Abstract |
CD20 antigen is expressed on nearly all human B-cells and B- lymphoma cells. Rituximab is a chimeric anti-CD20 monoclonal antibody with mouse variable and human constant regions. The toxicities of rituximab are mainly infusion-related, non-hematological grade 1 or 2 episodes. Of the 11 eligible patients enrolled in the phase I study in Japan, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m2 x 4 weekly infusions. The overall response rates in relapsed indolent B-cell lymphoma and mantle cell lymphoma were 61% (37/61) and 46% (6/13), respectively. Rituximab is a novel, effective anti- lymphoma agent with acceptable toxicities.
|
Authors | Kensei Tobinai |
Journal | Nihon rinsho. Japanese journal of clinical medicine
(Nihon Rinsho)
Vol. 60
Issue 1
Pg. 95-9
(Jan 2002)
ISSN: 0047-1852 [Print] Japan |
PMID | 11808346
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
- Antineoplastic Agents
- Immunoconjugates
- Yttrium Radioisotopes
- Rituximab
- ibritumomab tiuxetan
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
(immunology)
- Antineoplastic Agents
(therapeutic use)
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Humans
- Immunoconjugates
- Lymphoma, B-Cell
(therapy)
- Mice
- Radioimmunotherapy
- Rituximab
- Yttrium Radioisotopes
|